



1/13




FIG. 1A



2/13




FIG.1B




FIG.1C



3/13




FIG.2



4/13




FIG. 3B





FIG. 3A




5/13

○ K562/pal-protA + CONTROL • Fc γ 1	□ NO K562
● K562/pal-protA + B7-1 • Fc γ 1	◇ K562
■ K562/B7-1-TRANSFECTED	△ K562/protA + B7-1 • Fc γ 1



○ K562/pal-protA + CONTROL • Fc γ 1	□ NO K562
● K562/pal-protA + B7-1 • Fc γ 1	◇ K562
■ K562/B7-1-TRANSFECTED	△ K562/protA + B7-1 • Fc γ 1





6/13


B7-1-Fc γ ₁ PROTEIN TRANSFER

FIG. 5A


87-1-Fc γ ₁ PROTEIN TRANSFER

FIG. 5B



7/13




FIG. 6A




FIG. 6B



8/13




FIG. 7

O I P E
OCT 21 2002
PATENT & TRADEMARK OFFICE

9/13




FIG. 8



10/13




FIG. 9

OCT 21 2002
PATENT & TRADEMARK OFFICE

11/13




FIG.10



12/13

INTRATUMOR INJECTION OF COSTIMULATORS





FIG.11



13/13




FIG.12